natgillin/translations-raw huggingface dataset:
Hvis du har taget for meget REYATAZ oralt pulver
If you take more REYATAZ than you should
Hvis du ved en fejltagelse har taget for meget REYATAZ, skal du kontakte din HIV- læge eller nærmeste hospital og bede om råd.
If you accidentally take more REYATAZ oral powder than your doctor recommended, contact your HIV doctor at once or contact the nearest hospital for advice.
Almindelige: hovedpine gulsot i det hvide i øjnene opkastning, diarré, smerter i bughulen (ubehagelige mavesmerter), kvalme, fordøjelsesbesvær gulsot (hud og/ eller øjne bliver gule) udslæt lipodystrofi- syndrom (kropsændringer pga. ændringer i fedtfordelingen, ophobning eller tab af fedt), voldsom træthed Ikke almindelige: perifer neuropati (følelsesløshed, svaghed, prikken eller smerte i arme og ben) overfølsomhed (allergisk reaktion) usædvanlig træthed eller svaghed vægttab, vægtøgning, manglende appetit, øget appetit depression, angst, søvnforstyrrelser
Common: headache ocular icterus (presence of jaundice seen in the white part of the eyes) vomiting, diarrhoea, abdominal pain (stomach pain of discomfort), nausea, dyspepsia (indigestion) jaundice (yellowing of the skin and/ or eyes) rash lipodistrophy syndrome (body changes due to fat redistribution, accumulation, or loss of body fat), fatigue (extreme tiredness) Uncommon:
157 desorientering, hukommelsestab, svimmelhed, søvnighed, abnorme drømme besvimelse, højt blodtryk vejrtrækningsbesvær betændelse i bugspytkirtlen, irritation af slimhinden i mavesækken, sår i munden og forkølelsessår, smagsforstyrrelse, luft i maven, tør mund, udspilet mave leverbetændelse kløende udslæt, hårtab, kløe svind af muskelmasse, ledsmerter, muskelsmerter nyresten, blod i urinen, for meget protein i urinen, hyppig vandladning brystforstørrelse hos mænd brystsmerter, utilpashed, feber søvnløshed Sjældne: gangforstyrrelser væskeophobninger, hurtig eller uregelmæssig hjertebanken forstørrelse af lever og milt opsamling af væske under huden, eksem, udvidelse af årene muskelsmerter og - svaghed, der ikke er forårsaget af motion nyresmerter Ikke kendt:
156 peripheral neuropathy (numbness, weakness, tingling or pain in the arms and legs) hypersensitivity (allergic reaction) asthenia (unusual tiredness or weakness) weight decreased, weight gain, anorexia (loss of appetite), appetite increased depression, anxiety, sleep disorder disorientation, amnesia (loss of memory), dizziness, somnolence (sleepiness), abnormal dream syncope (fainting), hypertension (high blood pressure) dyspnoea (shortness of breath) pancreatitis (inflammation of the pancreas), gastritis (inflammation of the stomach), stomatitis aphthous (mouth ulcers and cold sores), dysgeusia (impairment of the sense of taste), flatulence (wind), dry mouth, abdominal distension hepatitis (inflammation of the liver) urticaria (itchy rash), alopecia (unusual hair loss or thinning), pruritus (itching) muscle atrophy (muscle shrinkage), arthralgia (joint pain), myalgia (aching muscles) nephrolithiasis (formation of kidney stones), hematuria (blood in the urine), proteinuria (excess protein in the urine), pollakiuria (increased frequency of urination) gynaecomastia (breast enlargement in men) chest pain, malaise (generally feeling unwell), fever insomnia (difficulty sleeping) Rare: gait disturbance (abnormal manner of walking) oedema (swelling), palpitation (fast or irregular heart beat) hepatosplenomegaly (enlargement of the liver and spleen) vesiculobullous rash (visible accumulation of fluid under the skin), eczema (skin rash), vasodilatation (widening of blood vessels) myopathy (aching muscles, muscle tenderness of weakness, not caused by exercise) kidney pain Not known:
Brug ikke REYATAZ efter den udløbsdato, der står på pakningen.
Do not use REYATAZ after the expiry date stated on the package and on the bottle label.
Anvend ikke REYATAZ oralt pulver hvis pulveret er blevet mørkegult eller brunt eller klumper.
Do not use REYATAZ oral powder if you notice the product has turned into a dark yellow or brown powder aggregated into one clump.
Spørg på apoteket, hvordan du skal aflevere medicinrester.
157 Medicines should not be disposed of via wastewater or household waste.
REYATAZindeholder:
What REYATAZ contains
158 Aktivt stof: atazanavir.
The active substance in REYATAZ is atazanavir.
Hver måleske med 1, 5 g oralt pulver indeholder 50 mg atazanavir (som sulfat).
One measuring spoon of 1.5 g oral powder contains 50 mg of atazanavir (as sulphate).
Øvrige indholdsstoffer: aspartam (E951), saccharose og orange- vaniljesmag.
The other ingredients are aspartame (E951), sucrose, and orange vanilla flavour.
REYATAZ oralt pulver fås i beholdere med 180 g pulver og leveres med en måleske af plastic.
REYATAZ oral powder is supplied in bottles containing 180 g of powder together with a plastic measuring spoon.
Farven af pulveret er hvidgult til svagt gult. REYATAZ fås også som kapsler.
REYATAZ also exists in capsules.
Ikke alle pakningsstørrelser er tilgængelige i alle lande.
However, not all pack sizes may be marketed in all countries.
Indehaver af markedsføringstilladelsen:
The marketing authorisation holder of REYATAZ is:
Fremstiller:
The manufacturer of REYATAZ is:
159 Ελλάδα BRISTOL- MYERS SQUIBB A. E.
Ελλάδα BRISTOL-MYERS SQUIBB A. E.
160 161
159 160
Ribavirin Teva er et lægemiddel, der indeholder det aktive stof ribavirin.
Ribavirin Teva is a medicine containing the active substance ribavirin.
Ribavirin Teva er et ‘ generisk lægemiddel ’.
Ribavirin Teva is a ‘ generic medicine’.
Det betyder, at Ribavirin Teva er identisk med et ‘ referencelægemiddel ’, som allerede er godkendt i Den Europæiske Union (EU), og som hedder Rebetol.
This means that it is similar to a ‘ reference medicine’ already authorised in the European Union (EU) called Rebetol.
Ribavirin Teva anvendes til behandling af voksne og børn i alderen 3 år eller ældre med kronisk hepatitis C (langvarig leverbetændelse forårsaget af hepatitis C- virus).
Ribavirin Teva is used to treat adults and children aged three years and older who have chronic (long- term) hepatitis C (a disease of the liver due to an infection with the hepatitis C virus).
Ribavirin Teva må aldrig anvendes alene, men kun sammen med et interferon (en anden type medicin, der anvendes ved hepatitis).
Ribavirin Teva must never be used on its own but only together with an interferon (another type of medicine used in hepatitis).
Hos voksne kan Ribavirin Teva anvendes til ‘ naive ’ patienter (som ikke tidligere er blevet behandlet) eller til patienter, hvor tidligere behandling, inklusive behandling med enhver type interferon alfa, med eller uden ribavirin, ikke har virket.
In adults, Ribavirin Teva can be used in ‘ naïve’ patients (who have not been treated before) or in patients in whom previous treatment including any type of interferon alfa, with or without ribavirin, did not work.
Ribavirin Teva anvendes enten i kombination med interferon alfa- 2b eller peginterferon alfa- 2b (herunder også til patienter, der desuden er smittet med hiv (human immundefektvirus)).
Ribavirin Teva is used either in combination with interferon alfa-2b or peginterferon alfa-2b (including for adults also infected with human immunodeficiency virus [HIV]).
Hos børn og unge kan Ribavirin Teva kun anvendes kombineret med interferon alfa- 2b hos ikke tidligere behandlede patienter uden hiv- infektion.
In children and adolescents, Ribavirin Teva can only be used in naïve patients without HIV infection and only in combination with interferon alfa-2b.
Dosis af Ribavirin Teva beregnes efter patientens legemsvægt og er mellem tre og syv kapsler dagligt.
The dose of Ribavirin Teva is based on the patient’ s body weight, and ranges from three to seven capsules a day.
Lægemidlet kan kun tages af patienter, der vejer mindst 47 kg.
It can only be taken by patients weighing at least 47 kg.
Ribavirin Teva menes at gribe ind i produktionen eller virkningen af viralt DNA og RNA, som er nødvendige for virusets overlevelse og formering.
RNA, which are needed for viruses to survive and multiply.
Anvendt alene er Ribavirin Teva uden virkning med hensyn til at udrydde hepatitis C- virus i kroppen.
Ribavirin Teva on its own has no effect on eliminating the hepatitis C virus from the body.
Da Ribavirin Teva er et generisk lægemiddel, har undersøgelserne været begrænset til at påvise, at det er bioækvivalent med referencelægemidlet (dvs. at de to lægemidler producerer samme mængde af det aktive stof i kroppen).
Because Ribavirin Teva is a generic medicine, studies have been limited to tests to demonstrate that it is bioequivalent to the reference medicine (i. e. that the two medicines produce the same levels of the active substance in the body).
Da Ribavirin Teva er et generisk lægemiddel, som er bioækvivalent med referencelægemidlet, anses benefit/ risk- forholdet for at være det samme som for referencelægemidlet.
Because Ribavirin Teva is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as those of the reference medicine.
Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at Ribavirin Teva i overensstemmelse med EU’ s krav har vist sig at være af sammenlignelig kvalitet og er bioækvivalent med Rebetol.
The Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Ribavirin Teva has been shown to have comparable quality and to be bioequivalent to Rebetol.
Det var derfor CHMP' s opfattelse, at fordelene opvejer de identificerede risici som for Rebetol.
Therefore, the CHMP’ s view was that, as for Rebetol, the benefit outweighs the identified risk.
Europa- Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Ribavirin Teva til Teva Pharma B. V. den 31. marts 2009.
The European Commission granted a marketing authorisation valid throughout the EU for Ribavirin Teva to Teva Pharma B. V. on 31 March 2009.
EU- nummer EU/ 1/ 09/ 509/ 001 EU/ 1/ 09/ 509/ 002 EU/ 1/ 09/ 509/ 003 EU/ 1/ 09/ 509/ 004
EMEA Number EU/ 1/ 09/ 509/ 001 EU/ 1/ 09/ 509/ 002 EU/ 1/ 09/ 509/ 003 EU/ 1/ 09/ 509/ 004
Navn Ribavirin Teva Ribavirin Teva Ribavirin Teva Ribavirin Teva
Name Ribavirin Teva Ribavirin Teva Ribavirin Teva Ribavirin Teva
Styrke 200 mg 200 mg 200 mg 200 mg
Strength 200 mg 200 mg 200 mg 200 mg
Lægemiddelform Kapsel, hård Kapsel, hård Kapsel, hård Kapsel, hård
Pharmaceutical Form Capsule, hard Capsule, hard Capsule, hard Capsule, hard
Indgivelsesvej Oral anvendelse Oral anvendelse Oral anvendelse Oral anvendelse
Route of Administration Oral use Oral use Oral use Oral use
Emballage blister (PVC/ PE/ PVdC) blister (PVC/ PE/ PVdC) blister (PVC/ PE/ PVdC) blister (PVC/ PE/ PVdC)
Packaging blister (PVC/ PE/ PVdC) blister (PVC/ PE/ PVdC) blister (PVC/ PE/ PVdC) blister (PVC/ PE/ PVdC)
Pakningsstørrelse 84 kapsler 112 kapsler 140 kapsler 168 kapsler
Package size 84 capsules 112 capsules 140 capsules 168 capsules
Hver Ribavirin Teva- kapsel indeholder 200 mg ribavirin
Each Ribavirin Teva capsule contains 200 mg of ribavirin For a full list of excipients, see section 6.1.
Ribavirin Teva er indiceret til behandling af kronisk hepatitis C og skal udelukkende anvendes som en del af en kombinationsbehandling med peginterferon alfa- 2b (voksne) eller interferon alfa- 2b (voksne, børn (3 år eller ældre) og unge).
Ribavirin Teva is indicated for the treatment of chronic hepatitis C and must only be used as part of a combination regimen with peginterferon alfa-2b (adults) or interferon alfa-2b (adults, children (3-years of age or older), and adolescents).
Der er ingen information om sikkerhed eller effekt ved anvendelse af Ribavirin med andre former for interferon (det vil sige foruden alfa- 2b) eller ved brug af Ribavirin med peginterferon alfa- 2b hos børn og unge.
There is no safety or efficacy information on the use of Ribavirin with other forms of interferon (i. e., not alfa-2b), or on the use of Ribavirin with peginterferon alfa-2b in children or adolescents.
Se venligst også produktresuméerne (SPC) for peginterferon alfa- 2b eller interferon alfa- 2b for information vedrørende ordination af disse specifikke lægemidler.
Please refer also to the peginterferon alfa-2b or interferon alfa-2b Summary of Product Characteristics (SPC) for prescribing information particular to that product.
4. 4).
Ribavirin Teva is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with chronic hepatitis C, not previously treated, without liver decompensation, with elevated alanine aminotransferase (ALT), who are positive for serum HCV-RNA (see section 4.4).
4. 4).
Additionally, Ribavirin Teva is indicated, in combination with peginterferon alfa-2b, for the treatment of adult patients with chronic hepatitis C, not previously treated, without liver decompensation, with elevated alanine aminotransferase (ALT), who are positive for serum HCV-RNA, including patients with clinically stable HIV co-infection (see section 4.4).
Ribavirin Teva er beregnet til anvendelse, i kombination med interferon alfa- 2b, til behandling af børn og unge i alderen 3 år eller ældre, som lider af tidligere ubehandlet kronisk hepatitis C uden leverdekompensation, og som er positive med hensyn til serum HCV- RNA.
Ribavirin Teva is intended for use, in a combination regimen with interferon alfa2b, for the treatment of children and adolescents 3 years of age and older, who have chronic hepatitis C, not previously treated, without liver decompensation, and who are positive for serum HCV-RNA.
Beslutning om at behandle bør tages individuelt fra patient til patient, idet der tages hensyn til tegn på sygdomsprogression såsom leverinflammation og fibrose, såvel som prognostiske faktorer for respons, HCV- genotype og virusmængde.
The decision to treat should be made on a case by case basis, taking into account any evidence of disease progression such as hepatic inflammation and fibrosis, as well as prognostic factors for response, HCV genotype and viral load.
Patienter, som tidligere har fået en mislykket behandling Voksne patienter:
Previous treatment failure patients Adult patients:
Ribavirin Teva er indiceret i kombination med interferon alfa- 2b til behandling af voksne patienter med kronisk hepatitis C, der tidligere har responderet (med normalisering af ALAT ved behandlingsafslutningen) på interferon alfa- monoterapi, men som efterfølgende har fået tilbagefald.
Ribavirin Teva is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with chronic hepatitis C who have previously responded (with normalisation of ALT at the end of treatment) to interferon alpha monotherapy but who have subsequently relapsed.
5. 1).
Additionally, Ribavirin Teva is indicated, in combination with peginterferon alfa-2b, for the treatment of adult patients with chronic hepatitis C who have failed previous treatment with interferon alpha
4. 2 Dosering og indgivelsesmåde
2 (pegylated or nonpegylated) and ribavirin combination therapy or interferon alpha monotherapy (see section 5.1).
Dosis, der skal indgives Dosis af Ribavirin Teva er baseret på patientens kropsvægt (Tabel 1).
Dose to be administered The dose of Ribavirin Teva is based on patient body weight (Table 1).
Ribavirin- kapsler skal indtages oralt hver dag fordelt på to doser (morgen og aften) samtidig med et måltid.
Ribavirin capsules are to be administered orally each day in two divided doses (morning and evening) with food.
Ribavirin Teva skal anvendes i kombination med enten peginterferon alfa- 2b (1, 5 mikrogram/ kg/ uge) eller interferon alfa- 2b (3 millioner internationale enheder [MIE] tre gange om ugen).
Ribavirin Teva must be used in combination with either peginterferon alfa-2b (1.5 micrograms/ kg/ week) or interferon alfa-2b (3 million international units [MIU] three times a week).
Ribavirin- dosis baseret på kropsvægt
Ribavirin dose based on body weight
Patientvægt (kg) < 65 65- 85 86- 105 > 105
weight (kg) < 65
Ribavirin- dosis 800 mg 1. 000 mg 1. 200 mg 1. 400 mg
Ribavirin dose 800 mg
Antal 200 mg kapsler 4a 5b 6c 7d
Number of 200 mg capsules 4a
a:
5b
2 morgen, 2 aften b:
a: b: c: d:
3 morgen, 3 aften d:
86 – 105 > 105 2 morning, 2 evening 2 morning, 3 evening 3 morning, 3 evening 3 morning, 4 evening
3 morgen, 4 aften
1,200 mg 1,400 mg
Ribavirin- kapsler i kombination med pegyleret interferon alfa- 2b:
Ribavirin Teva Capsules in combination with pegylated interferon alfa-2b:
5. 1).
Patients infected with virus genotype 1 who fail to achieve virological response at Week 12 are highly unlikely to become sustained virological responders (see also section 5.1).
• Genotype 1:
• Genotype 1:
Patienter, som udviser virologisk respons ved uge 12, bør fortsætte behandling i en periode på yderligere ni måneder (det vil sige i alt 48 uger).
For patients who exhibit virological response at week 12, treatment should be continued for another nine month period (i. e., a total of 48 weeks).
I undergruppen af patienter med genotype 1- infektion og lav virusmængde (< 600. 000 IE/ ml), som bliver HCV- RNA- negative ved behandlingsuge 4, og som stadig er HCV- RNA- negative ved uge 24, kan behandlingen enten stoppe efter denne 24 ugers behandlingsperiode eller fortsætte i yderligere 24 uger (dvs. en samlet 48 ugers behandlingsperiode).
In the subset of patients with genotype 1 infection and low viral load (< 600,000 IU/ ml) who become HCV-RNA negative at treatment week 4 and remain HCV-RNA negative at week 24, the treatment could either be stopped after this 24 week treatment course or pursued for an additional 24 weeks (i. e. overall 48 weeks treatment duration).
Imidlertid kan en samlet 24 ugers behandlingsperiode være forbundet med større risiko for tilbagefald end en 48 ugers behandlingsperiode (se afsnit 5. 1). • Genotype 2 eller 3:
However, an overall 24 weeks treatment duration may be associated with a higher risk of relapse than a 48 weeks treatment duration (see section 5.1). • Genotypes 2 or 3:
Det anbefales, at alle patienter behandles i 24 uger; undtaget er HCV/ hiv - co- inficerede patienter, som bør behandles i 48 uger. • Genotype 4:
It is recommended that all patients be treated for 24 weeks, except for HCV/ HIV co-infected patients who should receive 48 weeks of treatment. • Genotype 4:
Patienter inficeret med genotype 4 betragtes generelt som sværere at behandle, og begrænsede undersøgelsesresultater (n=66) tyder på, at de bør tilbydes en behandlingsperiode som for genotype 1.
In general, patients infected with genotype 4 are considered harder to treat and limited study data (n=66) indicate they are compatible with a duration of treatment as for genotype 1.
Samtidig infektion med HCV/ hiv Den anbefalede doseringsvarighed af HCV/ hiv- co- inficerede patienter er 48 uger uanset genotype.
HCV/ HIV Co-infection The recommended duration of dosing for HCV/ HIV co-infected patients is 48 weeks, regardless of genotype.
Forudsigelighed af respons og non- respons ved HCV/ hiv- co- infektion Tidligt virologisk respons i uge 12, defineret som et 2 log fald i viral load eller ikke- detekterbart
Predictability of response and non-response in HCV/ HIV Co-infection Early virological response by Week 12, defined as a 2 log viral load decrease or undetectable levels of HCV-RNA, has been shown to be predictive for sustained response.
3 niveau af HCV- RNA, har vist sig at være prædiktivt for et vedvarende respons.
The negative predictive value for sustained response in HCV/ HIV co-infected patients treated with Ribavirin in combination with
5. 1).
3 peginterferon alfa-2b was 99% (67/ 68; Study 1) (see section 5.1).
En positiv prædiktiv værdi på 50% (52/ 104; Undersøgelse 1) blev observeret for HCV/ hiv- co - inficerede patienter, der modtog kombinationsbehandling.
A positive predictive value of 50% (52/ 104; Study 1) was observed for HCV/ HIV co-infected patients receiving combination therapy.
Behandlingsvarighed – Genbehandling Forudsigelighed af vedvarende virologisk respons:
Duration of treatment - Retreatment Predictability of sustained virological response:
Alle patienter, uanset genotype, der har opnået serum HCV- RNA under målbar grænse i uge 12, bør modtage 48 ugers behandling.
All patients, irrespective of genotype, who have demonstrated serum HCV-RNA below the limits of detection at Week 12 should receive 48 weeks of therapy.
Det er ikke sandsynligt, at genbehandlede patienter, hvor det ikke lykkes at opnå virologisk respons i uge 12, vil opnå vedvarende virologisk respons efter 48 ugers behandling (se også pkt.
Retreated patients who fail to achieve virological response at Week 12 are unlikely to become sustained virological responders after 48 weeks of therapy (see also section 5.1).
Genbehandling af mere end 48 ugers varighed af ikke- responderende patienter med genotype 1 er ikke blevet undersøgt med kombinationsbehandling med pegyleret interferon alfa- 2b og ribavirin.
Retreatment duration greater than 48 weeks in non-responder patients with genotype 1 has not been studied with pegylated interferon alfa-2b and ribavirin combination therapy.
Ribavirin- kapsler i kombination med interferon alfa- 2b:
Ribavirin Capsules in combination with interferon alfa-2b:
I disse kliniske undersøgelser, i hvilke patienter blev behandlet i et år, var det usandsynligt, at patienter, der ikke viste et virologisk respons efter seks måneders behandling (HCV- RNA under laveste detektionsgrænse), fik vedvarende virologisk respons (HCV - RNA under laveste detektionsgrænse seks måneder efter afbrudt behandling).
During those clinical trials in which patients were treated for one year, patients who failed to show a virological response after six months of treatment (HCV-RNA below lower limit of detection) were unlikely to become sustained virological responders (HCV-RNA below lower limit of detection six months after withdrawal of treatment).
Beslutningen om at forlænge behandling til et år hos patienter med negativ HCV- RNA efter seks måneders behandling bør træffes på grundlag af andre prognostiske faktorer (såsom alder > 40 år, mandligt køn, brofibrose).
The decision to extend therapy to one year in patients with negative HCV- RNA after six months of treatment should be based on other prognostic factors (e. g., age > 40 years, male gender, bridging fibrosis).
(for patienter som vejer < 47 kg, eller som ikke er i stand til at synke kapsler, se venligst produktresume for ribavirin 40 mg/ ml oral opløsning).
(for patients who weigh < 47 kg, or are unable to swallow capsules, please refer to the SPC for ribavirin 40 mg/ ml oral solution).
I kliniske undersøgelser udført i denne population, blev ribavirin og interferon alfa- 2b benyttet i doser på henholdsvis 15 mg/ kg/ dag og 3 MIE/ m2 tre gange ugentligt (Tabel 2).
In clinical studies performed in this population ribavirin and interferon alfa-2b were used in doses of 2 15 mg/ kg/ day and 3 MIU/ m three times a week respectively (Table 2).
Ribavirin Teva- kapsler skal indtages oralt hver dag fordelt på to doser samtidig med et måltid (morgen og aften).
Ribavirin Teva capsules are to be administered orally each day in two divided doses with food (morning and evening).
Ribavirin pædiatrisk dosis baseret på kropsvægt
Ribavirin paediatric dose based on body weight
Patientvægt (kg) 47- 49 50- 65 > 65
Patient weight (kg) 47 - 49 50 - 65
Daglig Ribavirin- dosis 600 mg 800 mg Se venligst doseringstabel for
Ribavirin dose 600 mg 800 mg
Antal 200 mg kapsler 3 kapsler a 4 kapsler b voksne (Tabel 1)
Number of 200 mg capsules 3 capsulesa 4 capsulesb
1 morgen, 2 aften b:
1 morning, 2 evening b:
2 morgen, 2 aften
2 morning, 2 evening
Patienter, som ikke opnår virologisk respons efter 12 uger, har meget lille sandsynlighed for at blive vedvarende virologiske respondenter (negativ prædiktiv værdi 96%).
Patients who fail to achieve virological response at 12 weeks are highly unlikely to become sustained virological responders (negative predictive value 96%).
Vejledninger for dosisjustering blev udviklet i kliniske
Dose modification for all patients If severe adverse reactions or laboratory abnormalities develop during therapy with Ribavirin and peginterferon alfa-2b or interferon alfa-2b, modify the dosages of each product if appropriate, until the adverse reactions abate.